title: Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.
abstract: Epstein-Barr virus (EBV)-DNA was prospectively analyzed in plasma and mononuclear cells (MNCs) from peripheral blood in patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type, to evaluate the clinical significance for diagnosis, monitoring the tumor burden, and prognostication. Thirty-three patients were enrolled, and 32 were evaluable. Pretreatment plasma and MNC EBV-DNA was detectable in 14 (range, 50-71 000 copies/mL) and 6 patients (range, 20-780 copies/μg DNA), respectively, and both were well correlated (r = 0.8741, P < .0001). Detectable plasma EBV-DNA was associated with higher clinical stage (P = .02), presence of B symptoms (P = .02), worse performance status (P = .02), and higher serum soluble IL-2 receptor level (P < .0001). Twenty-two patients attained complete response. Plasma EBV-DNA level was significantly higher in nonresponders than in responders (mean, 16,472 vs 2,645 copies/mL; P = .02). Multivariate analysis showed clinical stage (hazard ratio, 9.0; 95% confidence interval, 1.8%-45.0%) and pretreatment plasma EBV-DNA (hazard ratio, 10.6; 95% confidence interval, 1.3%-87.0%) were significant prognostic factors. Three-year overall survival of plasma EBV-DNA positive and negative patients was 42.9% and 94.4%, respectively (P = .0009). Plasma was a preferable sample for this purpose in NK/T-cell lymphoma, nasal type, and EBV-DNA level was a good indicator for response and overall survival.
authors: Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan. r-suzuki@med.nagoya-u.ac.jp
authors: Ritsuro
authors: R
authors: Suzuki
authors: Motoko
authors: M
authors: Yamaguchi
authors: Koji
authors: K
authors: Izutsu
authors: Go
authors: G
authors: Yamamoto
authors: Kenzo
authors: K
authors: Takada
authors: Yasuaki
authors: Y
authors: Harabuchi
authors: Yasushi
authors: Y
authors: Isobe
authors: Hiroshi
authors: H
authors: Gomyo
authors: Tadashi
authors: T
authors: Koike
authors: Masataka
authors: M
authors: Okamoto
authors: Rie
authors: R
authors: Hyo
authors: Junji
authors: J
authors: Suzumiya
authors: Shigeo
authors: S
authors: Nakamura
authors: Keisei
authors: K
authors: Kawa
authors: Kazuo
authors: K
authors: Oshimi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004279:DNA, Viral / Q000097:blood / Q000378:metabolism; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000401:mortality / Q000821:virology; D005260:Female; D018628:Gene Dosage / Q000235:genetics; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D054391:Lymphoma, Extranodal NK-T-Cell / Q000276:immunology / Q000401:mortality / Q000821:virology; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000276:immunology / Q000821:virology*; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D004279:DNA, Viral